期刊文献+

低剂量卡培他滨同期联合放疗对中晚期食管癌的疗效观察 被引量:4

下载PDF
导出
摘要 目的:观察低剂量卡培他滨同步放疗治疗中晚期食管癌的近期疗效及毒副反应。方法:回顾性分析2004年1月-2005年12月收治的Ⅱ~Ⅲ期食管癌患者39例,其中放疗同步口服卡培他滨组(RT+X组)20例,单纯放疗组(RT组)19例,RT+X组自放疗开始之日起口服卡培他滨每天1000 m g/m^2,直到放疗结束。结果:RT+X组与RT组总有效率分别为95%、68.4%(P〈0.05),1年生存率分别为35%、31.6%(P〉0.05)。RT+X组主要的毒副反应为手足综合征,发生率为10%,RT组为0%,P〈0.05,有统计学意义。两组均有不同程度胃肠道反应,但均为Ⅰ~Ⅱ级,对症处理后未影响治疗。Ⅱ~Ⅲ级骨髓抑制RT+X组为25%(5例),RT组为15.8%(3例);Ⅳ级骨髓抑制RT+X组为5%(1例),RT组为0%(0例),两组无统计学意义。结论:小剂量卡培他滨与放疗联合,有协同作用且毒副作用小,容易耐受。
出处 《临床医药实践》 2008年第4期265-266,共2页 Proceeding of Clinical Medicine
  • 相关文献

参考文献10

  • 1Westerp M, Koppert L B,Buskens C J,et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction [J]. Virchows Arch,2005,446(5) :497.
  • 2Sun D R. Ten-year follow up of esophageal cancer treated by radical radiation therapy:analysis of 869 patients[J]. Int J Radiat Oncol Biol Phys, 1989,16: 329.
  • 3Devesa S S, Blot W J,Fraumeni J F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States [J]. Cancer, 1998, 83:2 049.
  • 4Bollschweiler E W,Olfgarten E,Gutschow C,et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males[J]. Cancer, 2001,92 : 549.
  • 5刘振化.食管癌肿瘤预后学[M].北京:北京科学技术文献出版社,1995.430.
  • 6Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral adminst ration to colorectal patients [ J]. Cancer Chemother Pharmacol,2000,45(4) :291-297.
  • 7Vent Urini M. Rational development of capecitabine [J]. Eur J Cancer,2002,38(Supp12) :3-9.
  • 8Sawada N,Ishikawa T,Sekiguchi F,et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine(Xeloda)in human cancer xenografts [J]. Clin Cancer Res, 1999, 5:2 948-2 953.
  • 9Cassidy J,Twelves C,Van Cutsem E,et al. First-Iine oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin [J]. Ann Oncol, 2002,13 : 566-575.
  • 10Vaishampayan U N,Ben-Josef E,Philip P A,et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies [J]. Int J Radiat Oncol Biol Phys,2002, 53:675-679.

同被引文献34

  • 1毕经旺,史杰,周芙蓉,韩少荣,刘欣,狄剑士,王宝成.卡培他滨联合草酸铂治疗晚期胃肠道恶性肿瘤(附52例报告)[J].山东医药,2006,46(15):60-61. 被引量:5
  • 2Westerp M,Koppert LB,Buskens CJ,et al.Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastroesophageal junction.Virchows Arch,2005,446(5):497.
  • 3Klauber N.Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-Me-thoxyestradiol and paclitaxe1.Cancer Res,2007,57(1):81.
  • 4Vent Urini M.Rational development of capeeitabine.Eur J Cancer,2002,38(Supp12):3-9.
  • 5Cox JD,Stetz J.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J].Radiat Oncol Biol Phys,1995,31:1341-1346.
  • 6Jay SC,Matthew DG,Arnold H,et al.Long term follow up of a prospectiver and omizedtrial (RTOG 8501) radiation therapy oncology group[J].Cancer,1999,281:1623-1627.
  • 7Wong R,Malthaner R.Combined chemotherapy and radiotherapy (withoutsurgery) compared with radiotherapy alone in localized carcinoma of the esophagus[J].Cochrane Database Systrev,2006,25(1):23-28.
  • 8Seung SK,Smith JW.Selective dose escalation of chemoradiotherapy for esophageal cancer:role of treatment intensification[J].Semin Oncol,2004,31(6):13-19.
  • 9周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:92-94.
  • 10张森,王余杰.三维适形放疗同步希罗达化疗治疗食管癌疗效分析[J].中外健康文摘,2011,8(44):11-13.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部